Risankizumab shows high efficacy and maintenance in improvement of response until week 52

Risankizumab has been recently approved for moderate‐to‐severe plaque psoriasis; however, real‐life studies are scarce. Analysis of possible predictor factors of treatment response are limited to body mass index (BMI) and previous biologic experience. Our objectives were to evaluate the effectivenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastorino, Luca, Susca, Sara, Megna, Matteo, Siliquini, Niccolò, Quaglino, Pietro, Ortoncelli, Michela, Avallone, Gianluca, Rubatto, Marco, Fabbrocini, Gabriella, Dapavo, Paolo, Ribero, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286040/
https://www.ncbi.nlm.nih.gov/pubmed/35156278
http://dx.doi.org/10.1111/dth.15378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286040/
https://www.ncbi.nlm.nih.gov/pubmed/35156278
http://dx.doi.org/10.1111/dth.15378

Ejemplares similares